Vudalimab (Anti-CTLA4 & PD-1)
Product Specifications
CAS Number
2329669-72-7
Synonyms
XmAb 20717
SKU
C00929-1mg
Target
PD-1/PD-L1
Applications
Apoptosis
Additionnal Information
Vudalimab is a bispecific antibody targeting PD-1 and CTLA-4 to inhibit immune checkpoint regulation and enhance immune responses. It is being developed for the treatment of advanced malignancies by promoting T-cell activation against tumors and metastatic castration-resistant prostate cancer (mCRPC) . M.W 125.43 kDa
Storage Conditions
-80°C (avoid freeze-thaw cycles)
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog